Epidemiology, disease progression, and economic burden of colorectal cancer

Journal of Managed Care Pharmacy

Volumn 13, Issue 6 SUPPL. C, 2007, Pages

  Benson III, Al B ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Bevacizumab; Capecitabine; Cetuximab; Colorectal cancer; FOLFOX; Irinotecan; Oxaliplatin; Panitumumab

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARCINOEMBRYONIC ANTIGEN; CELECOXIB; CETUXIMAB; CYCLOOXYGENASE 2 INHIBITOR; FLOXURIDINE; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; OXALIPLATIN; PANITUMUMAB; PLACEBO; PROTEIN MLH1; PROTEIN P53;

ADJUVANT THERAPY; ALOPECIA; ANEMIA; BARIUM ENEMA; BIOLOGICAL THERAPY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER INCIDENCE; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RISK; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMOPROPHYLAXIS; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COLONOSCOPY; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DEHYDRATION; DIARRHEA; DRUG APPROVAL; DRUG MECHANISM; DRUG WITHDRAWAL; FAT INTAKE; FEBRILE NEUTROPENIA; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; GENE MUTATION; GROUPS BY AGE; HAND FOOT SYNDROME; HEALTH ECONOMICS; HUMAN; HYPERTENSION; LEUKOPENIA; LIVER METASTASIS; LIVER RESECTION; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NON PROFIT ORGANIZATION; OCCULT BLOOD; PATIENT ADVOCACY; PATIENT CARE; PHARMACY; PREVALENCE; PROGNOSIS; RADIOFREQUENCY ABLATION; REVIEW; SENSORY NEUROPATHY; SIGMOIDOSCOPY; SOMATOSENSORY DISORDER; THROMBOCYTOPENIA; TREATMENT PLANNING; TUMOR VASCULARIZATION; TUMOR VOLUME; UNITED STATES; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; BIOLOGICAL PRODUCTS; COLORECTAL NEOPLASMS; COST OF ILLNESS; DISEASE PROGRESSION; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MASS SCREENING; NEOPLASM STAGING; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS;

EID: 35348972526     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Berenson A. Hope, at $4,200 a Dose. New York Times. October 1, 2006. Available at: http://www.nytimes.com/2006/10/01/business/yourmoney/ 01drug.html?ex=1317355200&en=7769a6e7aa9326d3&ei=5088&partner= rssnyt&emc=rss. Accessed November 1, 2006.
2. American Cancer Society. Cancer Facts & Figures 2006. Atlanta, GA: American Cancer Society; 2006.
3. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43-66.
4. Ries LAG, Eisner MP, Kosary CL, et al., eds. SEER Cancer Statistics Review, 1973-1997. Bethesda, MD: National Cancer Institute; 2000.
5. Penna C, Nordlinger B. Colorectal metastasis (liver and lung). Surg Clin North Am. 2002;82:1075-90, x-xi.
6. Fernandez FG, Drebin JA, Linehan DC, Dehdashti F, Siegel BA, Strasberg SM. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg. 2004;240(3):438-47. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid= 15319715. Accessed April 30, 2007.
7. Pawlik TM, Scoggins CR, Zorzi D, et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg. 2005;241(5):715-22. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid= 15849507. Accessed April 30, 2007.
8. Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg. 2004;240:644-57; discussion 657-58.
9. Kuriki K, Tajima K. The increasing incidence of colorectal cancer and the preventive strategy in Japan. Asian Pac J Cancer Prev. 2006;7:495-501.
10. Yamashita K, Arimura Y, Shimizu H, et al. Increased cyclooxygenase-2 expression in large flat colorectal tumors (laterally spreading tumors). J Gastroenterol. 2003;38:69-73.
11. Plummer SM, Hill KA, Festing MF, Steward WP, Gescher AJ, Sharma RA. Clinical development of leukocyte cyclooxygenase 2 activity as a systemic biomarker for cancer chemopreventive agents. Cancer Epidemiol Biomarkers Prev. 2001;10:1295-99.
12. Arber N, Eagle CJ, Spicak J, et al., and PreSAP Trial Investigators. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med. 2006;355:885-95.
13. Phillips RK, Wallace MH, Lynch PM, et al., and FAP Study Group. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut. 2002;50:857-60.
14. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med. 2000;342:1946-52.
15. Giardiello FM, Brensinger JD, Petersen GM, et al. The use and interpretation of commercial APC gene testing for familial adenomatous polyposis. N Engl J Med. 1997;336:823-27.
16. Ahsan H, Neugut AI, Garbowski GC, et al. Family history of colorectal adenomatous polyps and increased risk for colorectal cancer. Ann Intern Med. 1998;128:900-05.
17. Aaltonen LA, Salovaara R, Kristo P, et al. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med. 1998;338:1481-87.
18. Wijnen JT, Vasen HF, Khan PM, et al. Clinical findings with implications for genetic testing in families with clustering of colorectal cancer. N Engl J Med. 1998;339:511-18.
19. Pretlow TP, Barrow BJ, Ashton WS, et al. Aberrant crypts: putative preneoplastic foci in human colonic mucosa. Cancer Res. 1991;511:564-67.
20. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988;319:525-32.
21. Kinzler KW, Vogelstein B. Landscaping the cancer terrain. Science. 1998;280:1036-37.
22. Weber RV, Stein DE, Scholes J, Kral JG. Obesity potentiates AOM-induced colon cancer. Dig Dis Sci. 2000;45:890-95.
23. Morotomi M, Guillem JG, LoGerfo P, Weinstein IB. Production of diacylglycerol, an activator of protein kinase C, by human intestinal microflora. Cancer Res. 1990;50:3595-99.
24. Reddy BS, Simi B, Patel N, Aliaga C, Rao CV. Effect of amount and types of dietary fat on intestinal bacterial 7 alpha-dehydroxylase and phosphatidylinositol-specific phospholipase C and colonic mucosal diacylglycerol kinase and PKC activities during stages of colon tumor promotion. Cancer Res. 1996;56:2314-20.
25. AJCC Cancer Staging Handbook. 6th ed. New York: Springer-Verlag; 2002.
26. National Comprehensive Cancer Network, Inc. NCCN Clinical Practice Guidelines in Oncology. Colon cancer. Version 1.2007, February 23, 2007 Available at: http://www.nccn.org/professionals/physician_gls/PDF/colon/pdf. Accessed March 18, 2007
27. Hughes KS, Simon R, Songhorabodi S, et al. Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of patterns of recurrence. Surgery. 1986;100:278-84.
28. Gayowski TJ, Iwatsuki S, Madariaga JR, et al. Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathologic risk factors. Surgery. 1994;116:703-10; discussion 710-11.
29. Scheele J, Stang R, Altendorf-Hofmann A, Paul M. Resection of colorectal liver metastases. World J Surg. 1995;19:59-71.
30. Fong Y, Blumgart LH, Fortner JG, Brennan MF. Pancreatic or liver resection for malignancy is safe and effective for the elderly. Ann Surg. 1995;222(4):426-34.
31. Jenkins LT, Millikan KW, Bines SD, Staren ED, Doolas A. Hepatic resection for metastatic colorectal cancer. Am Surg. 1997;63:605-10.
32. Jamison RL, Donohue JH, Nagorney DM, Rosen CB, Harmsen WS, Ilstrup DM. Hepatic resection for metastatic colorectal cancer results in cure for some patients. Arch Surg. 1997;132:505-10; discussion 511.
33. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230(3):309-18.
34. Rougier P, Laplanche A, Huguier M, et al. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. J Clin Oncol. 1992;10:1112-18.
35. Martin RC 2nd, Scoggins CR, McMasters KM. A phase II study of radiofrequency ablation of unresectable metastatic colorectal cancer with hepatic arterial infusion pump chemotherapy. J Surg Oncol. 2006;93(5):387-93.
36. Lorenz M, Muller HH. Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma. J Clin Oncol. 2000;18:243-54.
37. Kemeny N, Huang Y, Cohen AM, et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer N Engl J Med. 1999;341:2039-48.
38. Chang AE, Schneider PD, Sugarbaker PH, Simpson C, Culnane M, Steinberg SM. A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg. 1987;206:685-93.
39. Allen-Mersh TG, Earlam S, Fordy C, Abrams K, Houghton J. Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases. Lancet. 1994;344:1255-60.
40. Wagman LD, Kemeny MM, Leong L, et al. A prospective, randomized evaluation of the treatment of colorectal cancer metastatic to the liver. J Clin Oncol. 1990;8:1885-93.
41. Curley SA, Izzo F, Delrio P, et al. Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies: results in 123 patients. Ann Surg. 1999;230:1-8.
42. Siperstein A, Garland A, Engle K, et al. Local recurrence after laparoscopic radiofrequency thermal ablation of hepatic tumors. Ann Surg Oncol. 2000;7:106-13.
43. de Baere T, Elias D, Dromain C, et al. Radiofrequency ablation of 100 hepatic metastases with a mean follow-up of more than 1 year. AJR Am J Roentgenol. 2000;175:1619-25.
44. Bowles BJ, Machi J, Limm WM, et al. Safety and efficacy of radiofrequency thermal ablation in advanced liver tumors. Arch Surg. 2001;136:864-69.
45. Solbiati L, Ierace T, Tonolini M, Osti V, Cova L. Radiofrequency thermal ablation of hepatic metastases. Eur J Ultrasound. 2001;13:149-58.
46. Bleicher RJ, Allegra DP, Nora DT, Wood TF, Foshag LJ, Bilchik AJ. Radiofrequency ablation in 447 complex unresectable liver tumors: lessons learned. Ann Surg Oncol. 2003;10:52-58.
47. Abdalla EK, Vauthey JN, Ellis LM, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg. 2004;239:818-25; discussion 825-27.
48. Berber E, Pelley R, Siperstein AE. Predictors of survival after radiofrequency thermal ablation of colorectal cancer metastases to the liver: a prospective study. J Clin Oncol. 2005;23:1358-64.
49. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000;343:905-14.
50. Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol. 2004;22:1209-14.
51. Grothey A, Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol. 2005;23:9441-42.